NASDAQ:HBIO - Nasdaq - US4169061052 - Common Stock - Currency: USD
0.67
+0.39 (+135.67%)
The current stock price of HBIO is 0.67 USD. In the past month the price increased by 88.04%. In the past year, price decreased by -78.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.44 | 152.41B | ||
DHR | DANAHER CORP | 25.57 | 136.31B | ||
A | AGILENT TECHNOLOGIES INC | 20.98 | 32.30B | ||
IQV | IQVIA HOLDINGS INC | 12.48 | 24.40B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 29 | 24.38B | ||
WAT | WATERS CORP | 29.83 | 21.14B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.7 | 15.12B | ||
ILMN | ILLUMINA INC | 25.31 | 13.34B | ||
RVTY | REVVITY INC | 18.64 | 10.83B | ||
ICLR | ICON PLC | 9.55 | 10.41B | ||
QGEN | QIAGEN N.V. | 19.57 | 9.75B | ||
TEM | TEMPUS AI INC | N/A | 9.42B |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2013-10-21. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
HARVARD BIOSCIENCE INC
84 October Hill Rd
Holliston MASSACHUSETTS 01746 US
CEO: James Green
Employees: 343
Phone: 15088938999
The current stock price of HBIO is 0.67 USD. The price increased by 135.67% in the last trading session.
The exchange symbol of HARVARD BIOSCIENCE INC is HBIO and it is listed on the Nasdaq exchange.
HBIO stock is listed on the Nasdaq exchange.
8 analysts have analysed HBIO and the average price target is 4.59 USD. This implies a price increase of 585.07% is expected in the next year compared to the current price of 0.67. Check the HARVARD BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HARVARD BIOSCIENCE INC (HBIO) has a market capitalization of 29.62M USD. This makes HBIO a Nano Cap stock.
HARVARD BIOSCIENCE INC (HBIO) currently has 343 employees.
The Revenue of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -7.04% in the next year. Check the estimates tab for more information on the HBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HBIO does not pay a dividend.
HARVARD BIOSCIENCE INC (HBIO) will report earnings on 2025-08-06, before the market open.
The PE ratio for HARVARD BIOSCIENCE INC (HBIO) is 22.33. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 0.67 USD. Check the full fundamental report for a full analysis of the valuation metrics for HBIO.
The outstanding short interest for HARVARD BIOSCIENCE INC (HBIO) is 3.15% of its float. Check the ownership tab for more information on the HBIO short interest.
ChartMill assigns a technical rating of 1 / 10 to HBIO. When comparing the yearly performance of all stocks, HBIO is a bad performer in the overall market: 94.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to HBIO. Both the profitability and financial health of HBIO have multiple concerns.
Over the last trailing twelve months HBIO reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -72.73% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -72.74% | ||
ROE | -391.31% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to HBIO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -23.5% and a revenue growth -7.04% for HBIO